Cell therapy weekly: Kymriah^® fails to meet primary endpoint in non-Hodgkin lymphoma study

This week: the Phase III BELINDA study investigating Kymriah® in patients with aggressive B-cell non-Hodgkin lymphoma failed to meet its primary endpoint; positive interim clinical data were reported for off-the-shelf, iPSC-derived NK cell programs for B-cell lymphoma; and a pioneering approach that delivers a one-time gene therapy to the putamen for AADC deficiency was published. The news highlights: Kymriah® fails to meet primary endpoint in non-Hodgkin lymphoma study Positive results reported for off-the-shelf, iPSC-derived NK cell programs for B-cell lymphoma One-time gene therapy demonstrates life-changing results in children with AADC deficiency   Kymriah® fails to meet primary endpoint in non-Hodgkin...